TG Therapeutics Inc. (TGTX)
NASDAQ: TGTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TGTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.57B
- P/E (TTM)
- 94.54
- Forward P/E
- 24.81
- EPS (TTM)
- $0.67
- Dividend yield
- None
- 52-week range
- 26.76 – 68.03
- Day range
- 63.12 – 65.64
- Volume / Avg
- 2.09M / 1.86M
- Beta
- —
- Shares outstanding
- 151.15M
52-week range
TGTX stock today
On Nov 20, TGTX ended the session at $63.34, shedding $1.54 (2.37%), versus the S&P 500's 3.70% decline. Shares are 6.9% below their 52-week high of $68.03, set on Nov 10, 2026 and 136.7% above the 52-week low of $26.76, near the top of the past year's range. TGTX is up 112.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 98.2%.
TG Therapeutics trades at 94.5x its trailing twelve-month earnings per share of $0.67. Its forward P/E of 24.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About TG Therapeutics
Company profileTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael S. Weiss Esq., J.D.
- Headquarters
- Morrisville, NC
- Employees
- 399
- Website
- tgtherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, TG Therapeutics generated $616.3 million in revenue, up 87.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $447.2 million (+1812.4% year over year), for a net margin of 72.6% versus a median of -5204.1% in the prior 5 years. Gross margin was 83.7% (down from 88.3%) and operating margin 20.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $616.29M | $329.00M | $233.66M | $2.79M | $6.69M |
| Growth | +87.32% | +40.80% | +8290.02% | -58.36% | +4300.66% |
| Net income | $447.18M | $23.38M | $12.67M | $-223.81M | $-348.10M |
| EPS (diluted) | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$69.43+9.61%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $2.43 vs $0.28
- Surprise
- +767.86%
TGTX news
All TGTX news- TG Therapeutics: The Price Already Pays For Growth That Ocrevus Copies Can Cut ShortSeeking Alpha
- 3 Stocks Rallying After Strong Q3 Earnings and Raised GuidanceNasdaqHAS, IDXX, TGTX
- TG Therapeutics: 3 Key Takeaways for Long-Term InvestorsNasdaqTGTX, BRK.A
- The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and MadrigalNasdaqBCRX, INSM, TGTX, MDGL
- TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock UpNasdaqTGTX, HALO, COLL, AMRX
- How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, NovartisInvestor's Business DailyTGTX, NVS
- IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%NasdaqIBRX, HALO, TGTX, AMRX
- CRMD to Acquire HRTX Assets for $223M Upfront to Expand PortfolioNasdaqCRMD, TGTX, HRTX, AMRX
TG Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SYRESpyre Therapeutics Inc. | 93.47 | -4.26% | $8.88B | vs TGTX |
| MDGLMadrigal Pharmaceuticals Inc. | 379.10 | -4.45% | $8.81B | vs TGTX |
| PRAXPraxis Precision Medicines Inc. | 300.43 | -3.37% | $8.40B | vs TGTX |
| SMMTSummit Therapeutics Inc. | 9.95 | -5.87% | $7.96B | vs TGTX |
| PTGXProtagonist Therapeutics Inc. | 121.40 | -2.11% | $7.92B | vs TGTX |
| RYTMRhythm Pharmaceuticals Inc. | 112.36 | -3.80% | $7.79B | vs TGTX |
| ALKSAlkermes plc | 44.94 | -2.69% | $7.55B | vs TGTX |
| BMRNBioMarin Pharmaceutical Inc. | 60.41 | -1.64% | $11.70B | vs TGTX |
Indexes, lists and sector
TG Therapeutics stock FAQ
What is TG Therapeutics's stock price today?
TGTX last traded at $63.34 as of Nov 20, 4:00 PM EST, down 2.37% on the day. Prices are delayed at least 15 minutes.
Does TG Therapeutics pay a dividend?
No. TG Therapeutics does not currently pay a regular cash dividend.
What is TGTX's P/E ratio?
TGTX trades at a trailing P/E ratio of 94.54 and a forward P/E of 24.81.
Who is TG Therapeutics's CEO?
Mr. Michael S. Weiss Esq., J.D. is the chief executive officer of TG Therapeutics Inc., which has about 399 employees.
Has TGTX ever split its stock?
Yes. The most recent TGTX stock split was a 100-for-5625 split on Apr 30, 2012, one of 2 splits on record.
What is the TGTX 52-week high?
The 52-week high for TGTX is $68.03 and the 52-week low is $26.76. The stock is currently 6.9% below its high.